Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy.
Goode
S
S
Tierney
G
G
Deighton
C
C
D018784:Abdominal Abscess / Q000139:chemically induced / Q000382:microbiology; D015746:Abdominal Pain / Q000139:chemically induced* / Q000382:microbiology; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000150:complications; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D018805:Sepsis / Q000139:chemically induced* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000150:complications; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept